Glycaemic control with liraglutide: The phase 3 trial programme

International Journal of Clinical Practice

Volumn 64, Issue SUPPL. 167, 2010, Pages 21-27

  Raskin, P ^a   Mora, P F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ACUTE PANCREATITIS; CALCITONIN BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FASTING PLASMA GLUCOSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POSTPRANDIAL PLASMA GLUCOSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; NAUSEA;

EID: 77956894291     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02496.x     Document Type: Review

References (22)

1. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964 2 : 20 1.
2. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004 36 : 761 5.
3. Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000 43 : 1664 9.
4. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002 45 : 195 202.
5. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008 57 (Suppl. 1 A164.
6. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduced endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 53 : 1187 94.
7. Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobsen J, Elbrønd B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes 2003 52 (Suppl. 1 A128.
8. Nauck MA, Hompesch M, Filipczak R et al. NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006 114 : 417 23.
9. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004 27 : 1335 42.
10. Vilsbøll T, Zdravkovic M, Le-Thu T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 30 : 1608 10.
11. Pratley R, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010 375 : 1447 56.
12. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203.
13. Garber A, Henry R, Ratner R et al. for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009 373 : 473 81.
14. Novo Nordisk AS. Liraglutide (Victoza®) summary of product characteristics [EMA approval; document on the Internet]. EMC web site; 2009. http://emc.medicines.org.uk/medicine/21986/SPC/ (accessed June 2010).
15. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009 32 : 84 90.
16. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009 26 : 268 78.
17. Zinman B, Gerich J, Buse J et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009 32 : 1224 30.
18. Russell-Jones D, Vaag A, Schmitz O et al. on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009 52 (10 2046 55.
19. Buse J, Rosenstock J, Sesti G et al. LEAD 6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 374 : 39 47.
20. Buse JB, Sesti G, Schmidt WE et al. Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010 33 (6 1300 3.
21. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
22. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.